Forest Bites At Stroke Clot Dissolver; Desmoteplase Could Have Nine-Hour Treatment Window

The company licenses U.S. and Canadian rights to Phase II plasminogen activator, derived from vampire bat saliva, from German firm PAION GmbH; desmoteplase is Forest’s first biologic product. The companies expect to initiate the rolling BLA submission as early as 2007.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet